louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03742115: Etoposide in the First-line Treatment of Adult EBV-HLH
Official title: A Randomized Controlled Trial of Etoposide in the First-line Treatment of Adult Epstein-barr Virus Associated Hemophagocytic Lymphohistiocytosis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Hemophagocytic Lymphohistiocytosis
Lead sponsor: Beijing Friendship Hospital
Sponsor class: OTHER
First posted: 2018-11-15
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: his study aimed to investigate the efficacy of etoposide as the first line therapy for adult Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.


Eligibility criteria: Inclusion Criteria:

1. Patients were older than 18 years of age
2. Diagnosed as EBV-Hemophagocytic Lymphohistiocytosis (HLH)
3. Patients did not receive any treatment for HLH before
4. Informed consent

Exclusion Criteria:

1. Heart function above grade II (NYHA)
2. Accumulated dose of doxorubicin above 300mg/m2 or epirubicin above 450mg/m2
3. Pregnancy or lactating Women
4. Allergic to Pegaspargase, doxorubicin or etoposide
5. Active bleeding of the internal organs
6. uncontrollable infection
7. history of acute and chronic pancreatitis
8. Participate in other clinical research at the same time

Primary outcomes:
measure: Overall response(complete response+ partial response) rate of Participants
timeFrame: Change from before and 2,4 weeks after initiating thearpy
Secondary outcomes:
measure: Compare survival between two arms
timeFrame: from the time patients received therapy up to 12 months or December 2020
Other outcomes:
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
timeFrame: through study completion, an average of 1 years
Locations:
city: Beijing
country: China
facility: Beijing Friendship Hospital, Capital Medical University
state: Beijing
Study officials:
References:
citation: Imashuku S, Kuriyama K, Teramura T, Ishii E, Kinugawa N, Kato M, Sako M, Hibi S. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol. 2001 May 15;19(10):2665-73. doi: 10.1200/JCO.2001.19.10.2665.
citation: Imashuku S, Kuriyama K, Sakai R, Nakao Y, Masuda S, Yasuda N, Kawano F, Yakushijin K, Miyagawa A, Nakao T, Teramura T, Tabata Y, Morimoto A, Hibi S. Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: a report from the HLH study center. Med Pediatr Oncol. 2003 Aug;41(2):103-9. doi: 10.1002/mpo.10314.
citation: Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G; Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002 Oct 1;100(7):2367-73. doi: 10.1182/blood-2002-01-0172.
Clinical trial NCT02040415: Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients
Official title: A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase Lll Clinical Trial to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Acute Back Pain
Lead sponsor: Daewon Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2014-01-20
Enrollment: 242
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical study is to determine whether or not DW-1030 is not inferior to eperisone HCl in efficacy and safety.


Eligibility criteria: Inclusion Criteria:

* Adult males/Females aged over 18 years
* Patients with symptom of Acute skeletomuscle myospasm and Back pain
* Patients with Pain VAS Value over 40 mm in Visit 2
* Subjects who voluntarily or legal guardian agreed with written consent

Exclusion Criteria:

* Patients with Back pain caused by spinal spondylosis, spinal stenosis, fractures, cancer, severe arthritis, osteoporosis, sciatica, infection
* Muscular patients such as myositis, muscular atrophy disease, increased muscle tone, myasthenia gravis
* Patients who had taken invasive procedures such as epidural injections or spinal stimulation to cure the back pain within 6 months from the screening point
* Patients who had taken passive physical therapy or ionphoresis within 12 hours from the screening point
* Patients with severe GI tract disorder, heart disease, hypertension
* Patients who had taken NSAIDS within 24hours from the screening point

Primary outcomes:
measure: Changes of Finger-to-Floor Distance(FFD) compared to baseline 7days after administration
timeFrame: 1, 3, 7 day
Secondary outcomes:
measure: Changes of 100mm Pain VAS
timeFrame: -3, 1, 3, 7 day
measure: Oswestry Disability Index (ODI)
timeFrame: 1, 3, 7 day
measure: Physician's Global Assessment
timeFrame: 7 day
measure: The number of using rescue drugs and the total amount
timeFrame: 1, 3, 7 days
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04766515: Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms
Official title: Multicenter Observational Prospective Study of Immune Checkpoint Inhibitors in Patients With Solid Neoplasms
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cancer
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2021-02-23
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with solid tumors treated with immune-checkpoints inhibitors

Brief summary: This prospective, multicenter observational study included all patients with solid neoplasms who received treatment with immune checkpoint inhibitors (ICIs) in clinical practice, regardless of tumor type, tumor stage, type of immunotherapy, or treatment lines. This study aimed to assess the use, effectiveness, and safety of ICIs for solid neoplasms in real-world populations, which can provide insights into clinical decisions associated with the use of ICIs for the treatment of cancer patients in the real-world setting.


Eligibility criteria: Inclusion Criteria:

* Age at least 18 years.
* Pathologically confirmed diagnosis of a solid tumor cancer.
* Patients receiving treatment with immune checkpoint inhibitors.
* Ability to understand and willingness to provide the informed consent.

Exclusion Criteria:

* Age \< 18 years.
* Patients with hematological malignancies or solid benign tumors.
* Mental disorders, drug abuse, and social condition that may negatively impact compliance in the opinion of the investigator.

Primary outcomes:
measure: Overall Survival
timeFrame: Three years
Secondary outcomes:
measure: Progression Free Survival
timeFrame: Three years
measure: Overall Objective Response Rate
timeFrame: At least 6 weeks after start of treatment
measure: Percentage of Participants With Adverse Events
timeFrame: Three years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
Study officials:
affiliation: Fudan University
name: Zhengfei Zhu, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Tongji Hospital
name: Qian Chu, MD
role: STUDY_DIRECTOR
affiliation: Shanghai Zhongshan Hospital
name: Jie Hu, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00124215: Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection
Official title: A Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation, Multi-center Therapeutic Trial of the Safety, Immunogenicity, and Efficacy of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, in Patients With Chronic Hepatitis C Infection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hepatitis C
Keywords: Hepatitis
HCV
vaccine
Hepatitis C Infection
Lead sponsor: GlobeImmune
Sponsor class: INDUSTRY
First posted: 2005-07-27
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The GI-5005 therapeutic vaccine or placebo will be injected under the skin of hepatitis C virus (HCV) subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections.


Eligibility criteria: Inclusion Criteria:

* Patients with chronic hepatitis C virus infection including treatment naive subjects as well as subjects who are partial responders and relapsers to prior interferon therapy
* \>18 years of age
* Negative skin test for hypersensitivity to saccharomyces cerevisiae.

Exclusion Criteria:

* Non-responders to previous interferon treatments
* Cirrhosis
* HCV treatment within 3 months
* Hepatitis B infection
* HIV infection

Primary outcomes:
measure: Safety and tolerability
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Pasadena
country: United States
facility: Huntington Medical Research Institutes
state: California
city: Denver
country: United States
facility: University of Colorado Health Sciences Center
state: Colorado
city: Miami
country: United States
facility: University of Miami
state: Florida
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
city: New York City
country: United States
facility: Weill Medical College of Cornell University
state: New York
Study officials:
References:
Clinical trial NCT03466515: Stem Cells Treatment of Complex Crohn's Anal Fistula
Official title: Stem Cells Treatment of Complex Crohns Perianal Fistula. A Pilot Clinical Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anal Fistula
Crohn Disease
Keywords: stem cells therapy
Lead sponsor: University of Southern Denmark
Sponsor class: OTHER
Collaborators: name: Odense University Hospital
First posted: 2018-03-15
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: pilot study with a maximum of 20 patients
Primary purpose: TREATMENT

Brief summary: A pilot study to investigate the safety and feasibility of stem cells treatment of complex anal fistula in patients with Crohn's disease.

Detailed description: Stem cells therapy in the management of soft tissue healing has been shown to be safe and feasible with encouraging short-term results both for crypto glandular and Crohns anal fistula. The long-term results are still insufficient but based on only a few studies conducted with small patient series and various techniques and type of stem cells. In the present study the patient's own adipose tissue derived regenerative cells (ADRCs) will be used. Traditionally the stem cells are injected into the fistula tract; however survival and retaining the stem cells in the fistula tract is problematic. Alternatively, one may apply stem cells enriched fatty tissue around and into the fistula tract. The aim of this project is to develop a method for treatment of patients with Crohns fistula. The results of conventional surgery are disappointing and followed by a high degree of recurrence and complications.

Eligibility criteria: Inclusion Criteria:

* patients with Crohn's anal fistulas and\> 18 yrs old.

Exclusion Criteria:

* Signs of suppuration around the fistula
* Active intestinal Crohn disease not in remission
* Malignancy within 5 years
* Previous radiotherapy of the abdomen and pelvis
* BMI under 18.5
* Coagulopathy
* Fistula with side branches
* Low anal fistula
* Verified syphilis, HIV, or hepatitis on screening test.

Primary outcomes:
measure: healing
timeFrame: 6 months
Secondary outcomes:
measure: recurrence
timeFrame: 6 months
measure: time to healing
timeFrame: 6 months
measure: major adverse effects
timeFrame: 6 months
measure: radiological healing
timeFrame: at 6 months
measure: functional outcome
timeFrame: 6 months
Other outcomes:
Locations:
city: Odense
country: Denmark
facility: Odense University Hospital
Study officials:
affiliation: University of Southern Denmark
name: Karam Matlub, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04446715: Comparison of Meperidine and Sufentanil Added to 0.5% Hyperbaric Bupivacaine for Spinal Anesthesia in Cesarean Section
Official title: Comparison of Clinical Effects of Meperidine and Sufentanil Added to 0.5% Hyperbaric Bupivacaine for Spinal Anesthesia in Patients Undergoing Cesarean Section
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Analgesia
Lead sponsor: Makassed General Hospital
Sponsor class: OTHER
First posted: 2020-06-25
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Subarachnoid block is a widely used anesthetic technique for cesarean section. To improve the quality of analgesia and prolong its duration, the addition of intrathecal opioids to local anesthetics has been encouraged.

In a double blind randomized controlled trial, 60 parturient women ASA 2-3 scheduled for elective cesarean delivery under spinal anesthesia will be randomly divided into 2 groups: Group 1 will receive sufentanil 5 μg and Group 2 will receive meperidine 12.5 mg. In every group, 0.5% heavy bupivacaine 10 will be added.

Detailed description: A questionnaire will be used to collect data. Patients' demographic and operative characteristics will be recorded. These include block level, heart rate, mean arterial pressure, nausea, vomiting, shivering and use of vasopressors. Post-operative data include pain, analgesic consumption, nausea and vomiting, as well as patients and surgeons satisfaction.

Eligibility criteria: Inclusion Criteria:

* pregnant women with American Society of Anesthesiologist (ASA) 2-3
* scheduled for elective cesarean section.

Exclusion Criteria:

* refuse to participate in the study,
* requiring emergency obstetric care,
* ASA IV or V,
* having systemic diseases,
* a known fetal anomaly,
* placenta previa,
* abruption placenta
* with a history of hypersensitivity or allergy to any of the study drugs,
* operation time longer than 1.5 hour,
* blood loss more than 1500 millilitres,
* those with any contraindication to the technique proposed,

Primary outcomes:
measure: First analgesic request time
timeFrame: 24 hours post operatively
Secondary outcomes:
measure: Analgesic requirements
timeFrame: 24 hours post operatively
Other outcomes:
Locations:
city: Beirut
country: Lebanon
facility: Makassed General Hospital
Study officials:
affiliation: Makassed General Hospital
name: Saleh Kanawati, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kanawati S, Barada MA, Naja Z, Rajab O, Sinno L, El Hasan J. Comparison of clinical effects of meperidine and sufentanil added to 0.5% hyperbaric bupivacaine for spinal anesthesia in patients undergoing cesarean delivery: a randomized controlled trial. J Anesth. 2022 Apr;36(2):201-209. doi: 10.1007/s00540-021-03031-6. Epub 2022 Jan 27.
Clinical trial NCT00917215: Effectiveness of Acupuncture for Asthma
Official title: Effectiveness of Acupuncture for Asthma: A Randomized, Sham-acupuncture and Waiting-list Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Asthma
Keywords: Asthma
Acupuncture
Pulmonary function
Quality of life
Lead sponsor: Korea Institute of Oriental Medicine
Sponsor class: OTHER_GOV
First posted: 2009-06-10
Enrollment: 45
Sex: ALL
Minimum age (years): 19
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: What is the trend of changes in asthmatic patients' daily peak expiratory flow (PEF) variability, pulmonary function, and quality of life (QOL) with acupuncture treatment on specific acupoints (CV22 and bilateral LU5, ST40, BL13, EXB1) compared with minimal acupuncture treatment (sham control group) on non-acupoints, and no acupuncture treatment (waiting list control group)?


Eligibility criteria: Inclusion Criteria:

* aged 19-70 years
* at least 12% improvement in forced expiratory volume in one second (FEV1)after the administration of short acting beta2 agonist.
* at least one typical asthmatic symptom
* using more than one routine anti-asthmatic medicine

Exclusion Criteria:

* acupuncture for asthma within 12 months of the study
* emergency department visit within one month of the study
* hospitalization for asthma within three months of the study
* severe upper respiratory tract infections within six weeks of the study
* systemic infections, cancers, autoimmune disorders, cardiac failures, myofacial infarcts,angina pectoris, renal failures or hepato-biliary diseases
* smoke more than ten cigarettes per day

Primary outcomes:
measure: Change of weekly average of peak expiratory flow (PEF)values in the morning at home
timeFrame: From 1 week of run-in period to the 4th week of treatment
Secondary outcomes:
measure: Forced expiratory volume in 1 second (FEV1) Baseline Dyspnea Index (BDI) Transition Dyspnea Index (TDI) Quality of Life Questionnaire for Adult Korean Asthmatics (QLQAKA)
timeFrame: Baseline and 2 weeks, 4 weeks, 6 weeks after Baseline (BDI for baseline only, TDI for 2, 4, and 6 weeks after baseline)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Division of Allergy & Respiratory System, Department of Oriental Internal Medicine, Kyunghee medical center
Study officials:
References:
Clinical trial NCT04682015: Effect of a WeChat Platform-based Management Intervention on Blood Pressure Control
Official title: Effect of a WeChat Platform-based Management Intervention on Blood Pressure Control: A Randomized Clinical Trial.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hypertension
Lead sponsor: First Affiliated Hospital of Wenzhou Medical University
Sponsor class: OTHER
First posted: 2020-12-23
Enrollment: 436
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: WeChat is the largest and most popular social media platform in China, In this study, investigators will evaluate the use of management program delivered via WeChat platform in patients with hypertension.


Eligibility criteria: Inclusion Criteria:

* Patients aged ≥ 18 years with confirmed diagnosis of hypertension
* Office systolic blood pressure (SBP)≥140 mmHg and/or diastolic blood pressure (DBP)≥90 mmHg, or ambulatory blood pressure monitoring (ABPM) indicating 24- hour SBP ≥130 mmHg and/or DBP ≥80 mmHg and/or daytime SBP ≥135 mmHg and/or DBP ≥85 mmHg and/or nocturnal SBP ≥120 mmHg and/or DBP ≥70 mmHg.
* Patients have smart phone and often use WeChat to communicate with others (including written interaction)
* Patients are willing and able to give informed consent for participation in the trial

Exclusion Criteria:

* Secondary hypertension
* Hypertensive emergency: defined as severe elevations in BP (SBP ≥180 mmHg and/or DBP≥120mmHg) associated with evidence of new or worsening target organ damage, including hypertensive encephalopathy, intracranial hemorrhage, cerebral hemorrhage, subarachnoid hemorrhage, cerebral infarction, heart failure, acute coronary syndrome (unstable angina, acute myocardial infarction), aortic dissection, perioperative hypertension, preeclampsia, and eclampsia
* Refractory hypertension: defined as failure to control BP despite lifestyle changes and use of at least 5 antihypertensive agents of different classes, including a thiazide-type diuretic and a mineralocorticoid receptor antagonist
* Pregnancy or lactation or having pregnancy plan during the study period
* Life expectancy less than 1 year
* Participation in another clinical study or clinical trial in the 3 months prior to the confirmation of eligibility or current user of WeChat platform provided by hypertension center of the first affiliated hospital of Wenzhou medical university

Primary outcomes:
measure: Proportion with controlled blood pressure at 12 months (defined by ambulatory blood pressure monitoring )
timeFrame: 12 months
Secondary outcomes:
measure: Systolic blood pressure (mmHg) at 12 months
timeFrame: 12 months
measure: Diastolic blood pressure (mmHg) at 12 months
timeFrame: 12 months
measure: Medication adherence at 12 months
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
affiliation: hypertension center of the first affiliated hospital of Wenzhou medical university
name: GaoJun Wu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06487715: Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Official title: Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Intraperitoneal Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: PHASE2
Conditions: Gastric Cancer Peritoneal Metastases
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
First posted: 2024-07-05
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: It is an open label, phase II study involved receiving albumin-bound paclitaxel plus S-1 combined with sintilimab and bevacizumab in patients with gastric cancer peritoneal metastasis.


Eligibility criteria: Inclusion Criteria:

* 18 to 75 years patients histologically or cytologically confirmed the presence of GC or gastroesophageal junction tumor with PM (HER2 negative). The ECOG performance status is 0-1 and the expected survival time is more than 3 months. Did not receive any therapy for GC within the last six months (chemotherapy, radiation therapy, or both).

Exclusion Criteria:

* Principal exclusion criteria: The obstruction of the cardia and pylorus affects the patient\&#39;s eating and gastric emptying, or has difficulty swallowing tablets. HER2-positive GC and gastroesophageal junction tumors. Subject with other malignancies, except for non-melanoma skin cancer or in-situ cervical carcinoma under adequate treatment, or other treated malignancies without evidence of recurrence for 5 years. Previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs that stimulate or co-inhibit T cell receptors (eg, CTLA-4, OX-40, CD137). Received systemic treatment with Chinese medicines or immunomodulatory drugs (including thymosin, interferon, interleukin, except for local use to control pleural effusion) with anti-tumor indications within 2 weeks before the first administration; Active autoimmune disease requiring systemic therapy (eg, disease-modifying drugs, glucocorticoids, or immunosuppressants) occurred within 2 years prior to first dose; Replacement therapy (such as thyroxine, insulin, or physiological glucocorticoids for adrenal or pituitary insufficiency, etc.) is not considered systemic therapy.

Primary outcomes:
measure: Overall survival rate
timeFrame: 1 year
Secondary outcomes:
measure: Progression free survival
timeFrame: 1 year
measure: Ascites drainage-free survival
timeFrame: 1 year
measure: Objective Response Rate
timeFrame: 1 year
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
Study officials:
References: